Differential Diagnosis and Clinical Implementation Strategies

Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects including immune effector cell-associated neurotoxicity syndrome (ICANS), which can manifest as weakness and create diagnostic overlap concerns with cancer-associated LEMS symptoms. She asks whether this complexity might complicate LEMS recognition and diagnosis.

Dr. Iams emphasizes maintaining strict ICANS surveillance parameters, defining it specifically as cognitive changes and decreased consciousness levels rather than broader neurologic symptoms. LEMS presents distinctly with muscle weakness (typically proximal), orthostatic hypotension, and reflex loss, allowing differentiation through nuanced neurologic evaluation approaches. He illustrates with a recent patient experiencing near-syncope and partial visual loss after tarlatamab initiation, where careful assessment revealed intact cognition and normal consciousness levels, confidently excluding ICANS diagnosis despite initial concerns.

The differential diagnosis approach involves systematic evaluation: muscle weakness predominantly affecting proximal muscles in LEMS cases, orthostatic hypotension, autonomic dysfunction, and reflex loss represent key distinguishing features. ICANS typically presents with confusion reported by family members or caregivers, with patients often unaware of confused episodes, providing clear diagnostic indicators when properly assessed.

Dr. Leal agrees, noting that cancer-associated LEMS typically manifests at initial diagnosis or disease progression, preceding tarlatamab initiation, allowing baseline neurologic status establishment. Proximal muscle weakness remains more characteristic of LEMS than tarlatamab-related effects, with additional LEMS features like dysarthria, diplopia, and autonomic dysfunction signs not typical of tarlatamab experiences. Timing considerations prove crucial for accurate differential diagnosis.

For clinical implementation strategies, Dr. Iams emphasizes appropriate activity when encountering LEMS-suggestive symptoms, particularly muscle weakness as the most common presentation. The previously mentioned analysis revealing only 3% screening rates among 50 patients with documented SCLC and muscle weakness should approach 100% testing rates. Documenting muscle weakness with SCLC warrants routine VGCC antibody testing given guideline support, specific available testing, and definitive treatment options for patients with ultimately better prognosis and longer treatment trajectories.

Dr. Leal reinforces comprehensive initial screening as standard practice, emphasizing neurologic symptom assessment while distinguishing SCLC extent-related symptoms from potential secondary neurologic processes. This requires quality history-taking, appropriate modeling for residents and fellows, and multidisciplinary team education including advanced practice providers and nursing staff. Once diagnostic triggers are identified, oncologists can proceed confidently with testing similar to liquid biopsy ordering for non-small cell lung cancer cases.

Importantly, chemotherapy initiation can proceed during result waiting periods since chemotherapy actually helps manage neurologic paraneoplastic syndromes, eliminating diagnostic delays as treatment barriers. Process establishment, neurology engagement when needed, escalation planning for additional therapies like prednisone or IVIg, quality of life focus, and supportive care measures using muscle function-improving medications all contribute to comprehensive patient care approaches addressing both cancer treatment and neurologic symptom management effectively.